Bioreactor technologies to support liver function in vitro
Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from...
| Main Authors: | , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Elsevier
2015
|
| Online Access: | http://hdl.handle.net/1721.1/99380 https://orcid.org/0000-0003-1441-6122 https://orcid.org/0000-0002-1801-5548 |
| _version_ | 1826216421144657920 |
|---|---|
| author | Neiman, Jaclyn A. Shepard Hughes, David J. Griffith, Linda G. Ebrahimkhani, Mohammad Reza Raredon, Micha Sam Brickman |
| author2 | Massachusetts Institute of Technology. Center for Gynepathology Research |
| author_facet | Massachusetts Institute of Technology. Center for Gynepathology Research Neiman, Jaclyn A. Shepard Hughes, David J. Griffith, Linda G. Ebrahimkhani, Mohammad Reza Raredon, Micha Sam Brickman |
| author_sort | Neiman, Jaclyn A. Shepard |
| collection | MIT |
| description | Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from prediction of metabolism and toxicity of small molecule drugs, to understanding off-target effects of proteins, nucleic acid therapies, and targeted therapeutics, to serving as disease models for drug development. Here we provide perspective on the evolving landscape of bioreactor-based models to meet old and new challenges in drug discovery and development, emphasizing design challenges in maintaining long-term liver-specific function and how emerging technologies in biomaterials and microdevices are providing new experimental models. |
| first_indexed | 2024-09-23T16:47:24Z |
| format | Article |
| id | mit-1721.1/99380 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T16:47:24Z |
| publishDate | 2015 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | mit-1721.1/993802022-09-29T21:30:03Z Bioreactor technologies to support liver function in vitro Neiman, Jaclyn A. Shepard Hughes, David J. Griffith, Linda G. Ebrahimkhani, Mohammad Reza Raredon, Micha Sam Brickman Massachusetts Institute of Technology. Center for Gynepathology Research Massachusetts Institute of Technology. Department of Biological Engineering Massachusetts Institute of Technology. Department of Chemical Engineering Massachusetts Institute of Technology. Department of Materials Science and Engineering Ebrahimkhani, Mohammad Reza Neiman, Jaclyn A. Shepard Raredon, Micha Sam Brickman Griffith, Linda G. Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from prediction of metabolism and toxicity of small molecule drugs, to understanding off-target effects of proteins, nucleic acid therapies, and targeted therapeutics, to serving as disease models for drug development. Here we provide perspective on the evolving landscape of bioreactor-based models to meet old and new challenges in drug discovery and development, emphasizing design challenges in maintaining long-term liver-specific function and how emerging technologies in biomaterials and microdevices are providing new experimental models. National Institutes of Health (U.S.) (R01 EB010246) National Institutes of Health (U.S.) (P50-GM068762-08) National Institutes of Health (U.S.) (R01-ES015241) National Institutes of Health (U.S.) (P30-ES002109) 5UH2TR000496-02 National Science Foundation (U.S.). Emergent Behaviors of Integrated Cellular Systems (CBET-0939511) United States. Defense Advanced Research Projects Agency. Microphysiological Systems Program (W911NF-12-2-0039) 2015-10-21T11:56:40Z 2015-10-21T11:56:40Z 2014-03 Article http://purl.org/eprint/type/JournalArticle 0169409X http://hdl.handle.net/1721.1/99380 Ebrahimkhani, Mohammad R., Jaclyn A. Shepard Neiman, Micha Sam B. Raredon, David J. Hughes, and Linda G. Griffith. “Bioreactor Technologies to Support Liver Function in Vitro.” Advanced Drug Delivery Reviews 69–70 (April 2014): 132–157. https://orcid.org/0000-0003-1441-6122 https://orcid.org/0000-0002-1801-5548 en_US http://dx.doi.org/10.1016/j.addr.2014.02.011 Advanced Drug Delivery Reviews Creative Commons Attribution http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Elsevier PMC |
| spellingShingle | Neiman, Jaclyn A. Shepard Hughes, David J. Griffith, Linda G. Ebrahimkhani, Mohammad Reza Raredon, Micha Sam Brickman Bioreactor technologies to support liver function in vitro |
| title | Bioreactor technologies to support liver function in vitro |
| title_full | Bioreactor technologies to support liver function in vitro |
| title_fullStr | Bioreactor technologies to support liver function in vitro |
| title_full_unstemmed | Bioreactor technologies to support liver function in vitro |
| title_short | Bioreactor technologies to support liver function in vitro |
| title_sort | bioreactor technologies to support liver function in vitro |
| url | http://hdl.handle.net/1721.1/99380 https://orcid.org/0000-0003-1441-6122 https://orcid.org/0000-0002-1801-5548 |
| work_keys_str_mv | AT neimanjaclynashepard bioreactortechnologiestosupportliverfunctioninvitro AT hughesdavidj bioreactortechnologiestosupportliverfunctioninvitro AT griffithlindag bioreactortechnologiestosupportliverfunctioninvitro AT ebrahimkhanimohammadreza bioreactortechnologiestosupportliverfunctioninvitro AT raredonmichasambrickman bioreactortechnologiestosupportliverfunctioninvitro |